{"id":142914,"date":"2022-07-26T20:26:54","date_gmt":"2022-07-27T01:26:54","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2022\/07\/researchers-find-link-between-genetic-mutations-and-cancer-treatment-resistance"},"modified":"2022-07-26T20:26:54","modified_gmt":"2022-07-27T01:26:54","slug":"researchers-find-link-between-genetic-mutations-and-cancer-treatment-resistance","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2022\/07\/researchers-find-link-between-genetic-mutations-and-cancer-treatment-resistance","title":{"rendered":"Researchers find link between genetic mutations and cancer treatment resistance"},"content":{"rendered":"<p><a class=\"aligncenter blog-photo\" href=\"https:\/\/lifeboat.com\/blog.images\/researchers-find-link-between-genetic-mutations-and-cancer-treatment-resistance.jpg\"><\/a><\/p>\n<p>Researchers from the University of Michigan Rogel Cancer Center, studying the molecular landscape of over 500 patients with an aggressive form of multiple myeloma, discovered a prevalence of activated key oncogenic pathways in these patients, much more than previously thought. Upwards of 45\u201365% of NF-\u03baB and RAS\/MAPK pathways each had alterations. The study was published in Nature Communications.<\/p>\n<p>Further, Arul Chinnaiyan, M.D., Ph.D., director of the Michigan Center for Translational Pathology, and his team found a link between mutations and RASopathies, a certain group of genetic syndromes, in patients with relapsed treatment-resistant <a href=\"https:\/\/medicalxpress.com\/tags\/multiple+myeloma\/\" rel=\"tag\" class=\"\">multiple myeloma<\/a>. This was the first observation of its kind.<\/p>\n<p>The team compared the molecular makeup of patients with untreated multiple myeloma to those with the relapsed treatment-resistant version of the disease. Comparing these patients allowed researchers to describe drivers of the more aggressive form of multiple myeloma.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Researchers from the University of Michigan Rogel Cancer Center, studying the molecular landscape of over 500 patients with an aggressive form of multiple myeloma, discovered a prevalence of activated key oncogenic pathways in these patients, much more than previously thought. Upwards of 45\u201365% of NF-\u03baB and RAS\/MAPK pathways each had alterations. The study was published [\u2026]<\/p>\n","protected":false},"author":427,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11,412],"tags":[],"class_list":["post-142914","post","type-post","status-publish","format-standard","hentry","category-biotech-medical","category-genetics"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/142914","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/427"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=142914"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/142914\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=142914"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=142914"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=142914"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}